Differential adhesion-inhibitory patterns of antibodies raised against two major variants of the NTS-DBL2X region of VAR2CSA  by Doritchamou, Justin et al.
D
t
J
S
A
a
b
c
d
e
f
a
A
R
R
A
A
K
P
P
M
V
V
1
t
P
s
i
p
i
p
T
v
0
hVaccine 31 (2013) 4516– 4522
Contents lists available at ScienceDirect
Vaccine
j our nal homep ag e: www.elsev ier .com/ locate /vacc ine
ifferential  adhesion-inhibitory  patterns  of  antibodies  raised  against
wo  major  variants  of  the  NTS-DBL2X  region  of  VAR2CSA
ustin  Doritchamoua,b,c, Pascal  Bigeyd,  Morten  Agertoug  Nielsene,f, Sédami  Gnidehoub,1,
em Ezinmegnonc, Aurore  Burgaind,  Achille  Massougbodji c, Philippe  Delorona,b,
li Salanti e,f,  Nicaise  Tuikue  Ndama,b,c,∗
PRES Sorbonne Paris Cité, Faculté de Pharmacie, Université Paris Descartes, France
Institut de Recherche pour le Développement, UMR216 Mère et enfant face aux infections tropicales, Paris, France
Centre d’Etude et de Recherche sur le paludisme associé à la Grossesse et à l’Enfance, Université d’Abomey-Calavi, Cotonou, Benin
Unité de pharmacologie chimique et génétique, Université Paris Descartes, ENSCP Chimie ParisTech, CNRS UMR8151, Inserm U 1022, 75006 Paris, France
Centre for Medical Parasitology, Department of International Health, Immunology and Microbiology, University of Copenhagen, Denmark
Centre for Medical Parasitology, Department of Infectious Diseases, Copenhagen University Hospital (Rigshospitalet), Denmark
 r  t  i  c  l  e  i  n  f  o
rticle history:
eceived 31 January 2013
eceived  in revised form 19 July 2013
ccepted 29 July 2013
vailable online 9 August 2013
eywords:
lasmodium falciparum
regnancy
alaria
AR2CSA
accine
a  b  s  t  r  a  c  t
Background:  VAR2CSA  is  a  large  polymorphic  Plasmodium  falciparum  protein  expressed  on  infected  ery-
throcytes  (IE)  that  allows  their  binding  in  the  placenta,  thus  precipitating  placental  malaria  (PM).  The
N-terminal  part  of  VAR2CSA  that  contains  the  binding  site to  placental  chondroitin  sulfate  A  (CSA)  is
currently  recognized  as  the  most  attractive  region  for  vaccine  development.  An  ultimate  challenge  is  to
deﬁne  epitopes  in this  region  that  induce  a broad  cross-reactive  adhesion  inhibitory  antibody  response.
Methods: Based  on  phylogenetic  data  that  identiﬁed  a  dimorphic  sequence  motif  in  the  VAR2CSA  DBL2X,
we  raised  antibodies  against  the  NTS-DBL2X  constructs  containing  one  sequence  or the  other  (3D7  and
FCR3)  and  tested  their  functional  properties  on P.  falciparum  isolates  from  pregnant  women  and  on
laboratory-adapted  strains.
Results: The  CSA  binding  inhibitory  capacity  of  the  antibodies  induced  varied  from  one parasite  isolate
to  another  (range,  10%–100%),  but  the  combined  analysis  of  individual  activity  highlighted  a  broader
functionality  that  increased  the  total  number  of isolates  inhibited.  Interestingly,  the  differential  inhibitory
effect  of the  antibodies  observed  on  ﬁeld  isolates  resulted  in  signiﬁcant  inhibition  of all  ﬁeld  isolates
tested,  suggesting  that  optimal  inhibitory  spectrum  on  ﬁeld  isolates  from  pregnant  women  might  be
achieved  with  antibodies  targeting  limited  variants  of  the  N-terminal  VAR2CSA.
Conclusions: Our  ﬁndings  indicate  that  the  NTS-DBL2X  region  of  VAR2CSA  can  elicit strain-transcending
anti-adhesion  antibodies  and  suggest  that  the  combination  of  the  two  major  variants  used  here could
 effecrepresent  the  basis  for  an
. IntroductionThe pathogenesis of malaria during pregnancy results from
he selective accumulation of Plasmodium falciparum infected
Abbreviations: PM,  placental malaria; IE, Pfalciparum-infected erythrocytes;
fEMP1,  Plasmodium falciparum erythrocyte membrane protein 1; CSA, chondroitin
ulfate  A; CSPG, chondroitin sulfate proteoglycan; DBL, Duffy binding-like; Id,
nter-domain; NTS, N-terminal sequence; DSM, dimorphic sequence motif; PBS,
hosphate buffered saline; BSA, bovine serum albumin; MFI, median ﬂuorescence
ntensity;  IPTp, intermittent preventive treatment during pregnancy.
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© 2013 Published by Elsevier Ltd.
erythrocytes (IE) in the intervillous spaces of the placenta [1,2].
This placental sequestration of IE severely increases the risks of
miscarriage, maternal anemia and low birth weight [3]. A member
of the P. falciparum erythrocyte membrane protein 1 (PfEMP1) fam-
ily, named VAR2CSA, is the parasite ligand for chondroitin sulfate
A (CSA) [4], a glycosaminoglycan present in the placenta. CSA is
considered to be the principal or only placental receptor for IE [5],
and selective disruption of the var2csa gene abrogates the binding
ability of IE to CSA in vitro [6]. VAR2CSA has been shown to be
predominantly expressed by placental isolates [7–9], and plasma
from individuals in malaria-endemic regions recognizes VAR2CSA-
expressing isolates in a sex-speciﬁc and parity-dependent manner
Open access under CC BY-NC-ND license.[10,11]. High plasma levels of anti-VAR2CSA antibodies are asso-
ciated with improved pregnancy outcomes in areas where women
are exposed to P. falciparum infections [10–12]. Recombinant
proteins reproducing selected extra-cellular domains of VAR2CSA
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re able to induce antibodies that efﬁciently inhibit CSA-binding
f IE [13–16]. The combination of these observations clearly
dentiﬁes VAR2CSA as the main target of acquired protective
mmunity to placental malaria (PM), and it is thus a candidate
or the development of a vaccine against this clinical malaria
yndrome.
VAR2CSA is a large protein with a molecular weight of
350 kDa formed by six Duffy binding-like domains (DBL1-6) and
our inter-domains (Id1-4) [17–19]. One of the major challenges in
accine development is to identify a minimal region that induces
train-transcending inhibitory antibodies. We  recently showed
hat antibodies to the N-terminal region of VAR2CSA display
road and strong adhesion-blocking capacity on ﬁeld isolates
20,21]. The identiﬁcation of the minimal CSA-binding in this
egion [22–24], suggests that efﬁcient anti-adhesion and very
ikely naturally-acquired protective antibodies bind to this part of
AR2CSA.
Another challenge to vaccine development is the sequence poly-
orphism present in VAR2CSA [8,18]. Antibodies raised against a
ingle FCR3 variant of NTS-DBL2X inhibited CSA-binding of ﬁeld
solates with an average inhibition level of 65% (range, 32–95%)
20], suggesting that antibodies against more than one variant
ould be needed for optimal protection. We  have previously iden-
iﬁed a dimorphic sequence motif (DSM) in the DBL2X domain of
AR2CSA [25] with two distinct phylogenetic groups of FCR3 and
D7 types. In this study, we examined the prevalence of each DSM
ype among P. falciparum parasites isolated from Beninese pregnant
omen. Furthermore, we examined the adhesion inhibitory capac-
ty of antibodies raised against each of the NTS-DBL2X variants on
eld and laboratory-maintained isolates.
. Materials and methods
.1.  Ethics statement
Pregnant women were included in this study after written
nformed consent was obtained. The study was approved by the
thical committee of the Faculty of Health Science (University of
bomey-Calavi, Benin). Animal immunization followed the FELASA
Federation of Laboratory Animal Science Associations) guidelines
nd was approved by the ethical committee afﬁliated to the Uni-
ersity Paris Descartes.
.2.  P. falciparum isolates
P.  falciparum IE were obtained from pregnant women  at Suru
éré maternity clinic, Cotonou, Benin. The study site is character-
zed by hyper-endemic malaria and high transmission with two
eaks during the two rainy seasons [26]. Pregnant women  attend-
ng antenatal visit or admitted for delivery were screened for
alaria using a rapid diagnostic test ParascreenTM (Zephyr Biomed-
cals Goa, India). Eight milliliters of venous blood were collected
rom women with plasmodial infection, in vacutainers with cit-
ate phosphate dextrose adenine anticoagulant. Two  hundred l
f erythrocyte pellets were stored at −20 ◦C for subsequent DNA
xtraction or homogenized in 10 volumes of TRIzol reagent (Invit-
ogen) and stored at −80 ◦C until RNA extraction. IE pellets were
mmediately cultured in vitro to trophozoite-stage as described
27]. Brieﬂy, isolates were grown in RPMI 1640 supplemented with
epes and l-glutamine (Lonza Biowhittaker), 0.3 g/L l-glutamine,
.05 g/L gentamicin, 5 g/L albumax. Cultures were grown for no
ore than 48 h before testing. Laboratory-adapted parasite strains
CR3, HB3 and NF54 were also grown and selected following sev-
ral panning on the choriocarcinoma cell line BeWo, as described
28]. 31 (2013) 4516– 4522 4517
2.3. DNA extraction and msp genotyping
DNA was extracted from 100 l of blood pellet using GeneJet
Genomic Puriﬁcation Kit (Fermentas) as recommended by the man-
ufacturer. Msp1 and msp2 genes were ampliﬁed by nested PCR using
speciﬁc primers [29]. Multiplicity of infection (MOI) was deter-
mined as the average number of distinct fragments detected in each
sample.
2.4. RNA extraction, cDNA synthesis and DBL2X genotyping
Total RNA was  extracted from samples stored in TRIzol reagent
(Invitrogen), as recommended by the manufacturer. To remove
potential contamination by genomic DNA (gDNA), RNA samples
were treated with DNase I (Invitrogen) for 15 min at room temper-
ature (RT). Absence of gDNA in RNA samples was  conﬁrmed by no
ampliﬁcation in real-time PCR using primers targeting the house-
keeping gene seryl-tRNA synthetase [4]. Reverse transcription was
performed using Thermoscript (Invitrogen) with random hexamer
primers, as recommended.
To  type the previously described DSM in the VAR2CSA DBL2X
domain of P. falciparum isolates [25], the DBL2X gene sequence
was selectively ampliﬁed from cDNA of each isolate using high
ﬁdelity Fusion Taq Polymerase. Primers forward 5′-TTAYCCCC-
AAGAACACA-3′ and reverse 5′-TTTTAAATTTTTTCCATGAA-3′ were
used under the cycling conditions 94 ◦C for 1 min, followed by 35
cycles of 94 ◦C for 30 s, 50 ◦C for 30 s and 68 ◦C for 50 s, with ﬁnal
extension at 68 ◦C for 10 min. PCR products were digested with
restriction enzymes BstCI (cuts the FCR3 DSM-type) and Hppy188I
(cuts the 3D7 DSM-type) for 1 h at 50 ◦C and 37 ◦C, respectively.
2.5. Antibody production and IgG preparation
The NTS-DBL2X fragments and the full-length sequence of the
optimized var2csa gene from the FCR3 and 3D7 parasite lines
were used to produce speciﬁc anti-VAR2CSA IgG, by DNA vacci-
nation as described [20]. Brieﬂy, DNA sequences were cloned into a
pVax1 vector derivative and fused to the mEPO signal sequence
as described [30]. Anaesthetized New-Zealand rabbits (Janvier-
France) were immunized by injection followed by application of
transcutaneous electric pulses in 5 sites of each longissimus dorsi
muscle. Animals were immunized at days 0, 30 and 60, and anti-
sera were collected at day 0 and 75 days. Total IgG were puriﬁed
from non-immunized (day 0) and immune rabbit (day 75) sera on
a Hi-Trap Protein G HP column, according to the manufacturer’s
recommendations (GE-Healthcare).
3.  Flow cytometry assay
The  reactivity of IgGs to the surface of P. falciparum IEs was  ana-
lyzed by ﬂow cytometry (FACS Calibur) as described [31]. Brieﬂy,
CSA-adhering lines (FCR3-Bewo and HB3-Bewo) and ﬁeld para-
site isolates were enriched by exposure to a strong magnetic ﬁeld
(VarioMACS and CS columns, Miltenyi). For each test 2 × 105 IE
were labeled with ethidium bromide, sequentially exposed to rab-
bit IgG (ﬁnal concentration approximately 10 g/ml) for 30 min,
and to FITC-conjugated anti-rabbit for 30 min  (Invitrogen). Data
were acquired, analyzed and the median ﬂuorescence intensity
(MFI) was determined. Labeling was deﬁned positive with MFI
ratio >1.2 (MFI with post-immunization IgG at day 75/MFI with
pre-immunization IgG (negative control at day 0), as described [31].3.1. Inhibition of binding assay (IBA)
Antibodies’ capacity to inhibit IE binding to chondroitin sulfate
proteoglycan (CSPG) was  explored using a static Petri dish assay, as
4518 J. Doritchamou et al. / Vaccine 31 (2013) 4516– 4522
Table  1
Characteristics of the study population.
Characteristics All women  (n = 123) Samples in Flow analysis (n = 47) Samples selected for IBAb (n = 18)
Age, years median (IQRa) 24 (20–30) 25 (21–30) 24 (21–30.5)
Median  of parity (IQR) 2 (1–4) 2 (1–4) 2.5 (1–4)
Gestational Age, median (IQR) 20 (15–28) 23 (12–29) 25.5 (17.5–31.3)
MOI,  median (IQR) 3 (2–4) 3 (1–4) 4 (2–4.5)
Parasitemia (IQR), parasites/l 1638.5 (311.5–18,177.5) 11340 (2937.3–54,996.5) 23,200 (3049–81300)
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Fig. 1. Distribution of the dimorphic sequence signatures of VAR2CSA DBL2X among
parasites infecting pregnant women. The dimorphic sequence motif (DSM) in DBL2X
that discriminates the var2csa alleles into two  subgroups (the 3D7 and FCR3 types)
was genotyped in parasites collected from pregnant women in Benin. Shown are
proportions of 3D7 type (white histogram), FRC3 type (black histogram) and the
mixture of both genotypes (hashed histogram). The multiplicity of infection (MOI)
NTS-DBL2X/FCR3 and P = 0.63 for NTS-DBL2X/3D7).
Fig. 2. Recognition of surface expressed VAR2CSA in ﬁeld isolates by IgG raised
against  VAR2CSA constructs. By ﬂow cytometry analysis, the expressed VAR2CSA
recognition  ability of IgG elicited to NTS-DBL2X constructs (NTS-DBL2X/3D7 anda Interquartile range.
b Inhibition binding assay.
escribed [20]. Brieﬂy, 20 l of 5 g/ml CSPG-Decorin (Sigma) or
0 g/ml bovine serum albumin (BSA) diluted in PBS were coated
s spots in a 100 mm × 15 mm Petri dish (Falcon 351029). Spots
ere incubated overnight at 4 ◦C in a humid chamber and blocked
ith 3% BSA. Late-stage IE with a parasitemia adjusted to 20%
n 1 × 105 cells were incubated with puriﬁed IgG (250 g/ml) or
00 g/ml of soluble CSA (Sigma). Cells were allowed to bind to
oated-plates for 15 min  at RT. Non-adherent cells were removed
y an automated washing system. Spots were ﬁxed with 1.5% glu-
araldehyde, stained with Giemsa and adherents IE were quantiﬁed
y microscopy.
.  Statistical analysis
All  experiments were performed in duplicate. Kruskall–Wallis,
ann–Whitney or Wilcoxon rank sum tests were used to compare
ontinuous variables while categorical variables were compared
sing the Fisher exact test. Prism software (version 4; Graphpad)
as used to plot data and statistical analyses were performed
y using STATA 12 software. Signiﬁcance was deﬁned at P val-
es ≤ 0.05.
. Results
.1. Determination of multiplicity of infection and molecular
yping of var2csa among parasites isolated from pregnant women
A  total of 1538 pregnant women were screened by RDT, from
ay through August 2012. Active P. falciparum infection was
onﬁrmed by microscopy on 123 women (8% prevalence). Charac-
eristics of the women enrolled in the study are presented in Table 1.
he mean MOI  of these isolates was 3.1 (range, 1–7). cDNA was
btained from 122 isolates. A PCR–RFLP was performed on all ﬁeld
solates to investigate the distribution of the DBL2X DSM. A restric-
ion enzyme-based analysis of this dimorphic region revealed the
resence of at least one of the dimorphic variants in transcripts
rom all parasites [25]. Fifty-four isolates (44%) transcribed only
he 3D7 DSM-type while the FCR3 DSM-type was the only geno-
ype detected in the transcripts of 47 isolates (39%). Both types of
ranscripts were detected in 21 isolates (17%), suggesting a mixture
f genotypes (Fig. 1).
.2.  Speciﬁc IgG induced against the NTS-DBL2X of FCR3 and 3D7
ypes  recognized isolates from pregnant women equally well
The  labeling of VAR2CSA expressing IE was measured by ﬂow
ytometry on 47 freshly isolated, in vitro matured P. falciparum-IE.
mong these isolates, 16 transcribed the 3D7 DSM, 21 the FCR3
SM and both genotypes were detected in 10 isolates. Both anti-
TS-DBL2X IgG against the 3D7 and FCR3 variants, and IgG raised
gainst the full-length VAR2CSA were used in this assay. IgG puri-
ed from non-immunized rabbit showed no signiﬁcant reactivity
ith all tested isolates. The range of MFI  values are shown in the
upplementary Table 1. Higher levels of reactivity were observed
ith antibodies against the full-length VAR2CSA (median = 1.4)was indicated for each category.
as compared to antibodies directed to the NTS-DBL2X fragments
(medians, 1.13 and 1.17 for 3D7 and FCR3 respectively) (P < 0.05).
No difference was found in the reactivity of the two types of anti-
NTS-DBL2X IgG (P = 0.59). This reactivity was  similar on isolates
expressing either the 3D7 or FCR3 DSM-type, (Fig. 2, P = 0.66 forNTS-DBL2X/FCR3) and to the full-length extra-cellular part of VAR2CSA of the FCR3
strain (NTS-DBL1-6/FCR3) was  assessed on ﬁeld isolates. Parasites were segregated
according to their DSM category (3D7, FCR3 or Mix  FCR3/3D7 DSM). Bar indicates
the  median of the MFI  ratio (MFI corresponding to the reactivity of IgG from hyper-
immune  animal/MFI corresponding to the reactivity of pre-bleed IgG).
J. Doritchamou et al. / Vaccine 31 (2013) 4516– 4522 4519
Fig. 3. Adhesion inhibitory activity of IgG raised against each of the two  variants of NTS-DBL2X on ﬁeld isolates. Binding inhibitory activity was evaluated on 18 freshly
collected P. falciparum isolates from pregnant women. Data are shown as percent of inhibition of each antibody that were normalized by CSA inhibition value (used here
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.3. Adhesion inhibitory capacity of anti-NTS-DBL2X IgGs
The  anti-adhesion capacity of the antibodies was further
ssessed on 18 isolates collected from pregnant women  in Benin.
eakly binding isolates (<250 IE/mm2) were excluded from this
esting. All of the 18 highly binders tested in the IBA were sig-
iﬁcantly labeled by anti-VAR2CSA IgGs while excluded isolates
ere weakly or not recognized (all P < 0.05). No difference was
bserved between excluded and included isolates regarding the
linical characteristics of parasite donors or the DSM distribution.
ix of the highly binding isolates expressed only the 3D7 DSM-
ype, 8 had only the FCR3 DSM-type, and a mixture of both types
as found in 4. Signiﬁcant adhesion inhibition was obtained with
ost-immunization IgG induced with both NTS-DBL2X constructs
Table 2). Data were further normalized against that of soluble
SA used as reference of the maximal binding inhibition as pre-
ented in Fig. 3. The interquartile range (IQR) of inhibitory activity
f post-immunization antibodies on all isolates was [51–100%] for
nti-NTS-DBL2X/FCR3 IgG and [55–100%] for anti-NTS-DBL2X/3D7.
o inhibition was observed with pre-immunization IgG. Sixteen
ut of the 18 isolates tested were signiﬁcantly inhibited (range,
3–100%) by anti-NTS-DBL2X/FCR3 IgG, whilst a high inhibitory
ctivity of anti-NTSDBL2X/3D7 was observed on 15 out of 18
solates tested (range, 50–100%). No signiﬁcant difference was
bserved overall (P = 0.84) in the activity of both types of antibodies
ccording to the DSM expressed by the isolates. However, signiﬁ-
antly contrasting activity of both antibodies can be observed on thee limit observed on a panel of pre-bleed rabbit sera was deﬁned at 40% inhibition.
 type, () for FCR3 DSM type ( ) for mixture of both genotypes.
same parasite (Fig. 3). Of the 8 isolates expressing only the FCR3-like
DSM, binding to CSPG for all was signiﬁcantly blocked by anti-NTS-
DBL2X/FCR3 (range, 43–100%) while binding of all but one isolate
was inhibited by antibodies against the 3D7 type. Likewise, of the 6
isolates transcribing the 3D7 DSM-type, only 4 were actually inhib-
ited by antibodies against each DSM-type, and 2 different isolates
were not inhibited. Isolates OPT161 and OPT144 expressing the 3D7
DSM-type, were inhibited by IgG speciﬁc to the NTS-DBL2X/3D7
variant, but not by antibodies raised against the FCR3 variant. The
opposite proﬁle was  observed with isolates OPT127 and OPT141
expressing the 3D7 DSM-type, which were inhibited by IgG spe-
ciﬁc to the FCR3 DSM-type and not by IgG against the homologous
DSM.
The two  IgG types were further tested individually or as a mix-
ture on laboratory-adapted parasite lines selected on BeWo cells.
The FCR3 and HB3 lines (which share the FCR3 DSM-type), and
the NF54 (3D7 background) were used. High inhibitory activity
was consistently obtained with antibodies toward IE belonging to
homologous DSM. Anti-NTS-DBL2X/FCR3 IgGs completely inhib-
ited CSA-binding of FCR3 and HB3 parasite lines (Fig. 4), but
had no effect on binding of the NF54 parasite line. Anti-NTS-
DBL2X/3D7 IgG highly inhibited (85%) the CSA-binding of NF54
parasite, and had only partial effect (20–40%) on the FCR3 and
HB3 parasite lines. Interestingly, a mixture of anti-NTS-DBL2X
IgG from both FCR3 and 3D7 strains conserved the ability to
almost totally abrogate (>82%) the binding of all 3 parasite lines
to CSPG.
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6. Discussion
Several lines of evidence identify VAR2CSA as the key target for
the development of a vaccine to prevent PM [4,7,8,32]. However,
constraints that include the high molecular weight of VAR2CSA
and inter-clonal polymorphisms are the major obstacles in the
process of vaccine development. An effective vaccine should elicit
broadly reactive antibodies that inhibit adhesion of IE to placenta
regardless of primary sequence variations between isolates. An
optimal region within VAR2CSA that retains functional and strain-
transcending epitopes was previously identiﬁed in the NTS-DBL2X
fragment [20,21]. As some isolates remained weakly or not inhib-
ited by antibodies raised against a single variant of NTS-DBL2X
construct from the FCR3 parasite strain, this invited further analy-
sis to understand the contribution of antigenic polymorphism to
the adhesion inhibitory capacity of anti-VAR2CSA antibodies. In
this study we  were interested in the DBL2X where a site with
dimorphic polymorphism was previously described. Although this
VAR2CSA domain taken alone does not bind CSPG, it was essen-
tial for optimal binding ability of a bigger construct and induction
of anti-adhesion antibodies [21,24]. The DSM deﬁned in DBL2X
can discriminate two major variants (FCR3 and 3D7) and the exis-
tence of this clear-cut dichotomy motivated the exploration of the
ability of antigens bearing these signatures of inducing antibod-
ies with similar properties. We  ﬁrst investigated the distribution
of the two  DSM variants among P. falciparum parasites isolated
from pregnant women  in Benin, and assessed the capacity of anti-
bodies generated against two  DSM-speciﬁc NTS-DBL2X constructs
to alter IE adhesion to CSPG. The antibodies raised against NTS-
DBL2X/FCR3 or NTS-DBL2X/3D7 variants were able to label the
surface of several isolates at a similar magnitude, irrespective of
the DSM type expressed. Higher level of labeling, however, was
noted with antibodies raised against the full-length construct of
VAR2CSA. This might be explained by the fact that surface recogni-
tion involves several epitopes on several domains, some of which
might be immuno-dominant and will increase the labeling ability
of antibodies to a larger protein than truncated ones. Interest-
ingly, antibodies raised against each NTS-DBL2X construct could
block the binding to CSPG of several ﬁeld isolates, suggesting that
these antibodies target strain-transcendent epitopes supporting IE
adhesion. The evaluation of the antibodies on the phenotypically
well-characterized laboratory parasite strains clearly highlighted
distinct inhibitory properties on the homologous and heterolo-
gous strains as deﬁned on the genetic background relative to
the DSM. This differential activity is also visible on ﬁeld isolates,
where one can easily note distinct patterns of inhibition by the
two kinds of antibodies on 5 of the 18 isolates analyzed. Although
the DBL2X dimorphic antigenic polymorphism does not seem to
totally explain the variation in the inhibitory capacity of the anti-
bodies on various ﬁeld isolates, as there is no signiﬁcant difference
in our data set to suggest that binding inhibitory antibodies are
DSM speciﬁc, it is still striking to note that the adhesion of those 5
ﬁeld isolates which was not inhibited by antibodies with speciﬁcity
for one construct was  indeed inhibited by antibodies with speci-
ﬁcity for the other construct. The combination of the overlapping
inhibitory patterns of both types of antibodies analyzed here and
showing differential inhibitory properties on some isolates actually
resulted in signiﬁcant inhibition of all isolates studied. We  assume
that the few critical and functional variations between isolates are
covered by the two  different antigenic constructs. This observation
is of major importance in the ongoing effort to create an optimal
VAR2CSA-based vaccine that will likely be essential for the induc-
tion of a sufﬁciently protective immunity. The data from this study,
although generated on a small number of samples, clearly suggest
that a higher proportion of parasite isolates would be targeted by
a multivalent vaccine approach comprising of two  genotypes or
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Fig. 4. Inhibition proﬁle of antibodies on selected and laboratory-adapted CSA-binding strains. FCR3, HB3 and NF54 strains selected on Bewo-cells (FCR3-Bewo, HB3-Bewo
and NF54-Bewo) were used to assess the ability of the induced antibodies to inhibit binding of 3 laboratory-adapted strains to CSPG. The in vitro functionality of the mixture
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ore. In addition, the mixing of the two antibody preparations did
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In conclusion, this study has demonstrated that the NTS-DBL2X
omain of both the FCR3 and 3D7 parasite strains is able to induce
train-transcendent adhesion-inhibitory antibodies. The combi-
ation of individual antibodies properties suggests that optimal
nhibitory spectrum on ﬁeld isolates might be achieved with anti-
odies targeting two variants of the N-terminal VAR2CSA. The
esults thus provide evidence on the relevance and the need for
olecular optimization of the VAR2CSA-based vaccines currently
n development. Conducting such studies on larger numbers of
amples is needed to further reﬁne these observations.
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